Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 175

1.

Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease.

Chung BK, Henriksen EKK, Jørgensen KK, Karlsen TH, Hirschfield GM, Liaskou E.

Hepatol Commun. 2018 Aug 6;2(8):956-967. doi: 10.1002/hep4.1200. eCollection 2018 Aug.

2.

Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.

Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F, Cardinale V, Ainsworth HF, Heneghan MA, Thorburn D, Bathgate A, Jones R, Neuberger JM, Battezzati PM, Zuin M, Taylor-Robinson S, Donato MF, Kirby J, Mitchell-Thain R, Floreani A, Sampaziotis F, Muratori L, Alvaro D, Marzioni M, Miele L, Marra F, Giannini E, Gaudio E, Ronca V, Bonato G, Cristoferi L, Malinverno F, Gerussi A, Stocken DD, Cordell HJ, Hirschfield GM, Alexander GJ, Sandford RN, Jones DE, Invernizzi P, Mells GF; Italian PBC Study Group and the UK–PBC Consortium.

Lancet Gastroenterol Hepatol. 2018 Sep;3(9):626-634. doi: 10.1016/S2468-1253(18)30163-8. Epub 2018 Jul 13.

PMID:
30017646
3.

Proximity to transplant center and outcome among liver transplant patients.

Webb GJ, Hodson J, Chauhan A, O'Grady J, Neuberger JM, Hirschfield GM, Ferguson JW.

Am J Transplant. 2018 Jul 7. doi: 10.1111/ajt.15004. [Epub ahead of print]

PMID:
29981195
4.

Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study.

McDonald N, Eddowes PJ, Hodson J, Semple SIK, Davies NP, Kelly CJ, Kin S, Phillips M, Herlihy AH, Kendall TJ, Brown RM, Neil DAH, Hübscher SG, Hirschfield GM, Fallowfield JA.

Sci Rep. 2018 Jun 15;8(1):9189. doi: 10.1038/s41598-018-27560-5.

5.

The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis.

Trivedi PJ, Reece J, Laing RW, Slaney E, Cooney R, Gunson BK, Kamarajah SK, Pinkney T, Thompson F, Muiesan P, Schlegel A, Hirschfield GM, Iqbal T, Ferguson J.

Aliment Pharmacol Ther. 2018 Aug;48(3):322-332. doi: 10.1111/apt.14828. Epub 2018 Jun 8.

PMID:
29882252
6.

Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis.

Jeffery HC, Braitch MK, Bagnall C, Hodson J, Jeffery LE, Wawman RE, Wong LL, Birtwistle J, Bartlett H, Lohse AW, Hirschfield GM, Dyson J, Jones D, Hubscher SG, Klenerman P, Adams DH, Oo YH.

Hepatol Commun. 2018 Feb 26;2(4):421-436. doi: 10.1002/hep4.1163. eCollection 2018 Apr.

7.

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ.

Gut. 2018 Sep;67(9):1568-1594. doi: 10.1136/gutjnl-2017-315259. Epub 2018 Mar 28.

8.

Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.

Webb GJ, Rahman SR, Levy C, Hirschfield GM.

Aliment Pharmacol Ther. 2018 Apr;47(8):1213-1219. doi: 10.1111/apt.14579. Epub 2018 Feb 22.

9.

Quality of life and primary sclerosing cholangitis: The business of defining what counts.

Arndtz K, Hirschfield GM.

Hepatology. 2018 Jul;68(1):16-18. doi: 10.1002/hep.29775. Epub 2018 May 2. No abstract available.

PMID:
29315689
10.

Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease.

Eddowes PJ, McDonald N, Davies N, Semple SIK, Kendall TJ, Hodson J, Newsome PN, Flintham RB, Wesolowski R, Blake L, Duarte RV, Kelly CJ, Herlihy AH, Kelly MD, Olliff SP, Hübscher SG, Fallowfield JA, Hirschfield GM.

Aliment Pharmacol Ther. 2018 Mar;47(5):631-644. doi: 10.1111/apt.14469. Epub 2017 Dec 22.

PMID:
29271504
11.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR.

Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12.

PMID:
29231188
12.

Insights into the management of Wilson's disease.

Kathawala M, Hirschfield GM.

Therap Adv Gastroenterol. 2017 Nov;10(11):889-905. doi: 10.1177/1756283X17731520. Epub 2017 Oct 3. Review.

13.

Cellular and Molecular Mechanisms of Autoimmune Hepatitis.

Webb GJ, Hirschfield GM, Krawitt EL, Gershwin ME.

Annu Rev Pathol. 2018 Jan 24;13:247-292. doi: 10.1146/annurev-pathol-020117-043534.

PMID:
29140756
14.

Deciphering the biology of IgG4-related disease: specific antigens and disease?

Haldar D, Hirschfield GM.

Gut. 2018 Apr;67(4):602-605. doi: 10.1136/gutjnl-2017-314861. Epub 2017 Nov 3. No abstract available.

15.

Primary sclerosing cholangitis and the management of uncertainty and complexity.

Arndtz K, Hirschfield GM.

Frontline Gastroenterol. 2017 Oct;8(4):260-266. doi: 10.1136/flgastro-2017-100815. Epub 2017 Jul 25. Review.

PMID:
29067151
16.

Genetic association studies and the risk factors for developing the "Immuno-bile-logic" disease primary biliary cholangitis.

Liaskou E, Hirschfield GM.

Hepatology. 2018 Apr;67(4):1620-1622. doi: 10.1002/hep.29603. Epub 2018 Feb 19. No abstract available.

PMID:
29063616
17.

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.

Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D; Obeticholic Acid PBC Monotherapy Study Group.

Hepatology. 2018 May;67(5):1890-1902. doi: 10.1002/hep.29569. Epub 2018 Jan 29.

18.

Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists.

Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM, Vierling JM, Hirschfield GM.

Clin Gastroenterol Hepatol. 2018 Feb;16(2):278-287.e7. doi: 10.1016/j.cgh.2017.09.062. Epub 2017 Oct 6.

PMID:
28993258
19.

Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.

Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, Janssen HLA, Sherman M, Hirschfield GM, Feld JJ.

J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248-1. doi: 10.1016/j.jhep.2017.07.033. [Epub ahead of print]

PMID:
28844936
20.

Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab.

Mumtaz S, Goh J, Hirschfield GM, Ferguson J, Cooper SC.

Frontline Gastroenterol. 2016 Oct;7(4):271-274. doi: 10.1136/flgastro-2016-100711. Epub 2016 Aug 5.

Supplemental Content

Loading ...
Support Center